RT Journal Article
SR Electronic
T1 Gene expression signatures identify biologically and clinically distinct tuberculosis endotypes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.13.20100776
DO 10.1101/2020.05.13.20100776
A1 Andrew R. DiNardo
A1 Tanmay Gandhi
A1 Jan Heyckendorf
A1 Sandra L. Grimm
A1 Kimal Rajapakshe
A1 Tomoki Nishiguchi
A1 Maja Reimann
A1 Jaqueline Kahari
A1 Qiniso Dlamini
A1 Christoph Lange
A1 Torsten Goldmann
A1 Sebastian Marwitz
A1 DZIF-TB cohort study group
A1 Abhimanyu
A1 Jeffrey D. Cirillo
A1 Stefan HE Kaufmann
A1 Mihai G. Netea
A1 Reinout van Crevel
A1 Anna M. Mandalakas
A1 Cristian Coarfa
A1 Members of the DZIF-TB cohort study group
YR 2021
UL http://medrxiv.org/content/early/2021/08/23/2020.05.13.20100776.abstract
AB Background In vitro, animal model, and clinical evidence suggests that tuberculosis is not a monomorphic disease, and that host response to tuberculosis is protean with multiple distinct molecular pathways and pathologies (endotypes). We applied unbiased clustering to identify separate tuberculosis endotypes with classifiable gene expression patterns and clinical outcomes.Methods A cohort comprised of microarray gene expression data from microbiologically confirmed tuberculosis patients were used to identify putative endotypes. One microarray cohort with longitudinal clinical outcomes was reserved for validation, as was one RNA-seq cohorts. Finally, a separate cohort of tuberculosis patients with functional immune results was evaluated to clarify stimulated from unstimulated immune responses.Results A discovery cohort, including 435 tuberculosis patients and 533 asymptomatic controls, identified two tuberculosis endotypes. Tuberculosis patient endotype A is characterized by increased expression of genes related to inflammation and immunity and decreased metabolism and proliferation; in contrast, endotype B increased activity of metabolism and proliferation pathways. An independent RNA-seq validation cohort, including 118 tuberculosis patients and 179 controls, validated the discovery results. Gene expression signatures for treatment failure were elevated in endotype A in the discovery cohort, and a separate validation cohort confirmed that endotype A patients had slower time to culture conversion, and a reduced incidence of cure. These observations suggest that endotypes reflect functional immunity, supported by the observation that tuberculosis patients with a hyperinflammatory endotype have less responsive cytokine production upon stimulation.Conclusion These findings provide evidence that metabolic and immune profiling could inform optimization of endotype-specific host-directed therapies for tuberculosis.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot applicable. Not a clinical trial.Funding StatementNIAID K23 AI141681-02, the Cancer Prevention Institute of Texas (CPRIT) RP170005, NIH P30 shared resource grant CA125123, and NIEHS grants 1P30ES030285 and 1P42ES0327725. CL is funded by the German Center for Infection Research (DZIF). JDC is funded in part from funds provided by the Texas A&M University System and National Institutes of Health grant AI104960. MGN is supported by an ERC Advanced Grant (#833247) and a Spinoza grant of the Netherlands Organization for Scientific Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:BCM IRB has approved studyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are publicly available as per the manuscript.